Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: A randomized, multicenter study

Transplant Infectious Disease

Volumn 12, Issue 1, 2010, Pages 23-30

  Vigano M ^a   Dengler, T ^b   Mattei, M F ^c   Poncelet, A ^d   Vanhaecke, J ^e   Vermes, E ^f   Kleinloog, R ^g   Li, Y ^h   Gezahegen, Y ^h   Delgado, J F ⁱ  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c CHU NANCY BRABOIS   (France)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f HENRI MONDOR HOSPITAL   (France)

^g Entabeni Hospital   (South Africa)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Cardiac transplantation; Cytomegalovirus; Everolimus; Mycophenolate mofetil; Proliferation signal inhibitor

Indexed keywords

ACICLOVIR; CYCLOSPORIN; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; EVEROLIMUS; FOSCARNET; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG WITHDRAWAL; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KAPLAN MEIER METHOD; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INFECTION;

ADULT; CYCLOSPORINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TREATMENT OUTCOME;

EID: 77149153725     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2009.00448.x     Document Type: Article

References (24)

1. Fishman JA, EmeryV, Freeman R, et al. Cytomegalovirus in transplantation - challenging the status quo. ClinTransplant 2007; 21 (2): 149-158.
2. Leroy F, Sechet A, Abou Ayache R, et al. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in highrisk renal transplant recipients.Transplant Proc 2006; 38 (7): 2324-2326.
3. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17 (4): 357-361.
4. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338 (24): 1741-1751.
5. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13 (1): 83-121.
6. Weill D. Role of cytomegalovirus in cardiac allograft vasculopathy. Transpl Infect Dis 2001; 3 (Suppl 2): 44-48.
7. Weis M, Kledal TN, Lin KY, et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004; 109 (4): 500-505.
8. Muhlestein JB, Horne BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000; 102 (16):1917-1923.
9. Hodson EM, Jones CA,WebsterAC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365 (9477): 2105-2115.
10. Koskinen PK, Kallio EA,Tikkanen JM, Sihvola RK, Häyry PJ, Lemström KB. Cytomegalovirus infection and cardiac allograft vasculopathy.Transpl Infect Dis 1999; 1 (2): 115-126.
11. Eisen HJ,Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349 (9): 847-858.
12. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.Transplantation 2007; 84: 1436-1442.
13. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart LungTransplant 2008; 27 (2): 141-149.
14. Lehmkuhl HB, Arizon J,Viganò M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.Transplantation 2009; 88 (1): 115-122.
15. Vitko S, Margreiter R,WeimarcW, et al.Three-year e?cacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5 (10):2521-2530.
16. Viganò M,Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart LungTransplant 2007; 26 (6): 584-592.
17. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110 (17): 2694-2700.
18. WebsterAC, LeeVW, Chapman JR, Craig JC.Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.Transplantation 2006; 81 (9): 1234-1248.
19. Ozaki KS, Câmara NOS, Galante NZ, Camargob LFA, Pacheco-Silva A. Decreased cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients. Int Immunopharmacol 2005; 5 (1): 103-106.
20. Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versushost disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110 (2): 490-500.
21. Johnson RA,Wang X, Ma X, Huong S, Huang E. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-k) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001; 75 (13): 6022-6032.
22. Ponticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int 2008; 21 (1): 2-10.
23. Valantine H, Zuckermann A. From clinical trials to clinical practice: an overviewof Certican (everolimus) in heart transplantation. J Heart LungTransplant 2005; 24 (4 Suppl): S185-S190.
24. Adam E, Melnick JL, DeBakey ME. Cytomegalovirus infection and atherosclerosis. Cent Eur J Public Health 1997; 5 (3): 99-106.